B细胞急性淋巴细胞白血病髓外病变特征及其对CAR-T细胞治疗的应答
该回顾性研究评估了CAR-T细胞治疗B-ALL非中枢神经系统髓外病变的动力学、毒性和疗效。在约180例筛查患者中,38例(21.1%)存在非中枢神经系统髓外病变;18例输注CAR-T细胞后,最佳应答时72.2%达骨髓微小残留病阴性完全缓解,并伴完全或部分髓外病变应答。髓外病变应答可能延迟且不充分,需系列FDG PET/CT监测。
要点
- 约180例复发/难治B-ALL中38例(21.1%)存在非中枢神经系统髓外病变。
- 18例输注CAR-T细胞后最佳应答时72.2%(13/18)达骨髓MRD阴性完全缓解。
- 髓外病变应答可延迟且不充分,需系列FDG PET/CT识别和监测。
核心结论
- CAR-T细胞对B-ALL非中枢神经系统髓外病变有活性,但应答可能延迟且不充分,尤其多发病灶时;系列FDG PET/CT扫描对识别和监测非中枢神经系统髓外病变是必要的。
研究设计与样本
- 回顾性综述,纳入本机构三项CAR试验(CD19、CD22和CD19/22)中筛查或入组的非中枢神经系统髓外病变B-ALL患者。
- 非中枢神经系统髓外病变依据组织学或影像学确定,排除脑脊液和中枢神经系统实质。
- 8年期间多个早期试验共筛查约180例复发/难治B-ALL患者。
主要发现
- 38例(21.1%)在18-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG PET/CT)成像上表现为孤立性非中枢神经系统髓外病变(n=5)或合并骨髓/非中枢神经系统髓外病变(n=33)。
- 接受CAR-T细胞输注的亚组(18次输注)在输注前后行FDG PET/CT扫描以监测应答。
- 最佳应答时,72.2%(13/18)患者显示骨髓微小残留病阴性完全缓解,并伴非中枢神经系统髓外病变完全(n=7)或部分(n=6)应答。
- 非中枢神经系统髓外病变对CAR-T细胞的应答延迟(n=3),残留非中枢神经系统髓外病变显著;罕见观察到不一致结局(骨髓应答但髓外病变无应答)(n=2)。
- 部分患者出现非中枢神经系统髓外病变部位特有的CAR相关毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells effectively eradicate medullary B-cell acute lymphoblastic leukemia (B-ALL) and can traffic to and clear central nervous system (CNS) involvement. CAR T-cell activity in non-CNS extramedullary disease (EMD) has not been well characterized. We systematically evaluated CAR T-cell kinetics, associated toxicities, and efficacy in B-ALL non-CNS EMD. We conducted a retrospective review of B-ALL patients with non-CNS EMD who were screened for/enrolled on one of three CAR trials (CD19, CD22, and CD19/22) at our institution. Non-CNS EMD was identified according to histology or radiographic imaging at extramedullary sites excluding the cerebrospinal fluid and CNS parenchyma. Of ∼180 patients with relapsed/refractory B-ALL screened across multiple early-phase trials over an 8-year period, 38 (21.1%) presented with isolated non-CNS EMD (n = 5) or combined medullary/non-CNS EMD (n = 33) on 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging. A subset receiving CAR T cells (18 infusions) obtained FDG PET/CT scans preinfusion and postinfusion to monitor response. At best response, 72.2% (13 of 18) of patients showed a medullary minimal residual disease-negative complete remission and complete (n = 7) or partial (n = 6) non-CNS EMD response. Non-CNS EMD responses to CAR T cells were delayed (n = 3), and residual non-CNS EMD was substantial; rarely, discrepant outcomes (marrow response without EMD response) were observed (n = 2). Unique CAR-associated toxicities at non-CNS EMD sites were seen in select patients. CAR T cells are active in B-ALL non-CNS EMD. Still, non-CNS EMD response to CAR T cells may be delayed and suboptimal, particularly with multifocal disease. Serial FDG PET/CT scans are necessary for identifying and monitoring non-CNS EMD.
引用
- Holland EM, Yates B, Ling A, et al. Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood Adv. 2022. PMID: 34920453. doi:10.1182/bloodadvances.2021006035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。